Congestive Heart Failure (CHF) is a major heart disease with high mortality rates. CHF has several characteristic symptoms: dyspnea, orthopnea, cardiac asthma, weakness, fluid retention, and others.

There are more than five million CHF patients in the United States alone, about 100,000 of whom are at an advanced stage with survival expectancy of 50% in two years and a poor quality of life. The condition of CHF patients usually worsens with time. Although some patients survive many years, progressive disease is associated with an overall annual mortality rate of 10%.

The costs of hospitalization due to CHF exceeded $16 billion in 2008 and are increasing from year to year. In 2006, an estimated 807,100 men and women over 65 were hospitalized for heart failure, up from 348,866 in 1980, an increase of 131%.

There is no gold standard for diagnosis of CHF or prognosis of deterioration. Given the high deterioration and death risk in case of a false negative decision, and the high cost of hospitalization in case of a false positive decision, there is a need for a rapid, simple-to-use and low-cost method that can improve decision making related to future hospitalization of CHF patients.